This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2014 Jul 1;32(19):1979-86.

doi: 10.1200/JCO.2014.55.4139. Epub 2014 Jun 2.

Past, present, and future challenges in breast cancer treatment

George W Sledge¹, Eleftherios P Mamounas², Gabriel N Hortobagyi³, Harold J Burstein⁴, Pamela J Goodwin⁵, Antonio C Wolff⁶

Affiliations

Affiliations

¹ Stanford University School of Medicine, Stanford, CA gsledge@stanford.edu.
² University of Florida Health Cancer Center, Orlando, FL.
³ MD Anderson Cancer Center, Houston, TX.
⁴ Dana-Farber Cancer Institute, Boston, MA.
⁵ Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada, and.
⁶ Johns Hopkins Cancer Center, Baltimore, MD.

PMID: 24888802
PMCID: PMC4879690
DOI: 10.1200/JCO.2014.55.4139

Past, present, and future challenges in breast cancer treatment

George W Sledge et al. J Clin Oncol. 2014.

. 2014 Jul 1;32(19):1979-86.

doi: 10.1200/JCO.2014.55.4139. Epub 2014 Jun 2.

Authors

George W Sledge¹, Eleftherios P Mamounas², Gabriel N Hortobagyi³, Harold J Burstein⁴, Pamela J Goodwin⁵, Antonio C Wolff⁶

Affiliations

¹ Stanford University School of Medicine, Stanford, CA gsledge@stanford.edu.
² University of Florida Health Cancer Center, Orlando, FL.
³ MD Anderson Cancer Center, Houston, TX.
⁴ Dana-Farber Cancer Institute, Boston, MA.
⁵ Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada, and.
⁶ Johns Hopkins Cancer Center, Baltimore, MD.

PMID: 24888802
PMCID: PMC4879690
DOI: 10.1200/JCO.2014.55.4139

No abstract available

PubMed Disclaimer

Similar articles

Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Costa SD, Caputo A, Kaufmann M; German Breast Group. von Minckwitz G, et al. Breast Cancer Res. 2008;10(2):R30. doi: 10.1186/bcr1989. Epub 2008 Apr 1. Breast Cancer Res. 2008. PMID: 18380893 Free PMC article. Clinical Trial.
[Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer. Its relation with molecular subtypes].
Ruano R, Ramos M, García-Talavera JR, Ramos T, Rosero AS, González-Orus JM, Sancho M. Ruano R, et al. Rev Esp Med Nucl Imagen Mol. 2014 Nov-Dec;33(6):340-5. doi: 10.1016/j.remn.2014.04.003. Epub 2014 May 21. Rev Esp Med Nucl Imagen Mol. 2014. PMID: 24856234 Spanish.
c-erbB-2 and the "triple-state" in early breast carcinomas.
Sivridis E, Stamos C, Fiska A, Nikolettos N, Koukourakis MI, Giatromanolaki A. Sivridis E, et al. Med Oncol. 2010 Sep;27(3):578-84. doi: 10.1007/s12032-009-9252-6. Epub 2009 Jun 23. Med Oncol. 2010. PMID: 19548127
[Modern pharmacological therapy of breast cancer].
Láng I, Kahán Z, Hitre E, Dank M, Rubovszky G, Horváth Z, Kásler M. Láng I, et al. Orv Hetil. 2012 Jan 15;153(2):56-65. doi: 10.1556/OH.2012.29257. Orv Hetil. 2012. PMID: 22217685 Review. Hungarian.
A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Jerusalem G, Bachelot T, Barrios C, Neven P, Di Leo A, Janni W, de Boer R. Jerusalem G, et al. Cancer Treat Rev. 2015 Feb;41(2):94-104. doi: 10.1016/j.ctrv.2014.12.011. Epub 2014 Dec 30. Cancer Treat Rev. 2015. PMID: 25575443 Review.

See all similar articles

Cited by

Breast Cancer Survivorship, Quality of Life, and Late Toxicities.
Nardin S, Mora E, Varughese FM, D'Avanzo F, Vachanaram AR, Rossi V, Saggia C, Rubinelli S, Gennari A. Nardin S, et al. Front Oncol. 2020 Jun 16;10:864. doi: 10.3389/fonc.2020.00864. eCollection 2020. Front Oncol. 2020. PMID: 32612947 Free PMC article. Review.
Identification and validation of a prognostic risk model based on caveolin family genes for breast cancer.
Tang Q, Wang S, Di Z, Li H, Xu K, Hu X, Di M. Tang Q, et al. Front Cell Dev Biol. 2022 Sep 6;10:822187. doi: 10.3389/fcell.2022.822187. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 36147736 Free PMC article.
Surgical Tumor Resection Deregulates Hallmarks of Cancer in Resected Tissue and the Surrounding Microenvironment.
Chaubal R, Gardi N, Joshi S, Pantvaidya G, Kadam R, Vanmali V, Hawaldar R, Talker E, Chitra J, Gera P, Bhatia D, Kalkar P, Gurav M, Shetty O, Desai S, Krishnan NM, Nair N, Parmar V, Dutt A, Panda B, Gupta S, Badwe R. Chaubal R, et al. Mol Cancer Res. 2024 Jun 4;22(6):572-584. doi: 10.1158/1541-7786.MCR-23-0265. Mol Cancer Res. 2024. PMID: 38394149 Free PMC article.
The Biphasic Effect of Flavonoids on Oxidative Stress and Cell Proliferation in Breast Cancer Cells.
Xi X, Wang J, Qin Y, You Y, Huang W, Zhan J. Xi X, et al. Antioxidants (Basel). 2022 Mar 24;11(4):622. doi: 10.3390/antiox11040622. Antioxidants (Basel). 2022. PMID: 35453307 Free PMC article.
A Stilbenoid Isorhapontigenin as a Potential Anti-Cancer Agent against Breast Cancer through Inhibiting Sphingosine Kinases/Tubulin Stabilization.
Subedi L, Teli MK, Lee JH, Gaire BP, Kim MH, Kim SY. Subedi L, et al. Cancers (Basel). 2019 Dec 5;11(12):1947. doi: 10.3390/cancers11121947. Cancers (Basel). 2019. PMID: 31817453 Free PMC article.

See all "Cited by" articles

References

1. J Natl Cancer Inst Monogr; NIH Consensus Development Conference on the Treatment of Early-Stage Breast Cancer; June 18-21, 1990; Bethesda, Maryland. 1992. pp. 1–187. - PubMed
1. Tuttle TM, Jarosek S, Habermann EB, et al. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol. 2009;27:1362–1367. - PubMed
1. Carpin LB, Bickford LR, Agollah G, et al. Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells. Breast Cancer Res Treat. 2011;125:27–34. - PubMed
1. Wapnir IL, Anderson SJ, Mamounas EP, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol. 2006;24:2028–2037. - PubMed
1. Fisher B, Anderson S, Fisher ER, et al. Significance of ipsilateral breast tumour recurrence after lumpectomy. Lancet. 1991;338:327–331. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal